Knowledge & News

Life Sciences Report 2015

Published June 2015

We have been through a decade of intense research into treatments for rare diseases, thanks in large part to the many government incentives in place to encourage investment and R&D. Meanwhile, as the problem of antibiotic resistance attracts more and more headlines, levels of research into new classes of antibiotics remain low. Vaccines continue to prove a vital tool in the prevention of widespread conditions, although we are now also seeing a growing focus on therapeutic vaccines.

In this year's Life Sciences Report, we have reviewed patent filing data over the last decade in these three key areas: medicines for rare diseases, vaccines and antibiotics. Each showed distinct trends in terms of filing volumes and the patent applicants themselves.

Editor

Gareth Williams

Gareth Williams Partner Cambridge (UK) Chartered (UK) and European Patent Attorney

Authors

Richard Gibbs

Richard Gibbs Partner Glasgow (UK) Chartered (UK) and European Patent Attorney

Mike Gilbert

Mike Gilbert Partner London (UK) Solicitor (UK)

Donald McNab

Donald McNab Principal Associate Edinburgh (UK) Chartered (UK) and European Patent Attorney

Yann Robin

Yann Robin Principal Associate Aberdeen (UK) Glasgow (UK) Chartered (UK) and European Patent Attorney

Mairi Rudkin

Mairi Rudkin Senior Associate Glasgow (UK) Chartered (UK) and European Patent Attorney

Andrea Williams

Andrea Williams Senior Associate Cambridge (UK) Chartered (UK) and European Patent Attorney

Subscribe image

You may also be interested in...

.
Protect, enforce, commercialise
Article

Protect, enforce, commercialise

Patent attorneys, trade mark attorneys, and lawyers – under one roof

.
Business Intelligence Q2 2020<BR/>Q2 2020
Newsletters

Business Intelligence Q2 2020
Q2 2020

POSTED 16 June 2020

Find the right person

Find the office that suits you

Click here to view our offices

>